Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

52.59 -0.92 (-1.72%)
Streaming Delayed Price Updated: 10:59 AM EST, Jan 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
34 35 Next >
News headline image
Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades Stock ↗
Stifel has upgraded Editas Medicine Inc (NASDAQ: EDIT), saying the company's sickle cell disease candidate, EDIT-301's progress, has received minimal credit from investors. 
Via Benzinga
News headline image
Why Editas Medicine Stock Is Soaring Today ↗
Investors are cheering a big analyst upgrade for the gene-editing stock. 
Via The Motley Fool
News headline image
If I Could Only Buy 3 Stocks in 2023, I'd Pick These ↗
These stocks have what it takes to grow in leaps and bounds. 
Via The Motley Fool
News headline image
Crispr Therapeutics, And CRISPR Gene-Editing, Face Their Make-Or-Break Moment ↗
The FDA is within three months of making a decision on the first-ever CRISPR-based drug. 
Via Investor's Business Daily
News headline image
2 Bargain Growth Stocks to Buy Hand Over Fist ↗
Both stocks have declined in recent times. 
Via The Motley Fool
News headline image
Don’t Miss the Boom: 3 Pharma Stocks Set to Explode Higher ↗
These pharma stocks could boom in the coming years, riding their diversified pipelines with massive addressable markets higher. 
Via InvestorPlace
News headline image
2 No-Brainer Biotech Stocks to Buy Right Now ↗
You can get in early on these potential winners. 
Via The Motley Fool
News headline image
From Dust to Diamonds: 7 Undervalued Stocks With Sparkling Prospects ↗
Are you looking to invest in undervalued stocks? Here are sever undervalued stocks with sparkling prospects. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023 ↗
 
Via Benzinga
News headline image
Are Gene Therapy Stocks The Market's Next Big Winners?
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
2 Cathie Wood Stocks to Buy Hand Over Fist Right Now ↗
These two high-tech stocks could dramatically outperform the broader market in the years ahead. 
Via The Motley Fool
News headline image
$10,000 Invested in These Growth Stocks Could Make You a Fortune Over the Next 10 Years ↗
I favor holding onto these players for the long term to truly benefit from their earnings potential. 
Via The Motley Fool
News headline image
Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio ↗
These two biotechs have a lot in common, but one is much better capitalized. 
Via The Motley Fool
News headline image
Flee to Healthcare Stocks if Recession Rears its Head?
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends. 
Via MarketBeat
Topics Economy
News headline image
Where Will CRISPR Therapeutics Be in 5 Years? ↗
The company hasn't performed well in the past five years, but things could change. 
Via The Motley Fool
News headline image
1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know ↗
Good medicines aren't always good business. 
Via The Motley Fool
News headline image
2 Top Trends to Invest $500 In Right Now ↗
Early investors in these trends may reap the rewards over time. 
Via The Motley Fool
News headline image
Looking for Growth? These Companies' Revenue May Skyrocket ↗
Catalysts on the horizon could drive gains in these top stocks. 
Via The Motley Fool
News headline image
If You Invested $30,000 in CRISPR Therapeutics in 2016, This Is How Much You Would Have Today ↗
The returns are impressive, but will they continue to be so? 
Via The Motley Fool
News headline image
Better Growth Stock: Recursion Pharmaceuticals vs. CRISPR Therapeutics ↗
They're both liable to grow by a lot, but one of them is a safer bet in the near term. 
Via The Motley Fool
News headline image
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point? ↗
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions. 
Via Investor's Business Daily
News headline image
3 Top Healthcare Stocks Defying the Bear Market ↗
Revenue at all three companies improved last quarter, and their share prices have followed suit. 
Via The Motley Fool
News headline image
Better Bull Market Buy: CRISPR vs. Medtronic Stock ↗
Investors may look for growth stocks ahead of the next bull market. 
Via The Motley Fool
News headline image
3 Biotech Blockbusters to Turn $5,000 Into $50,000 ↗
These transformative early-stage biotech stocks can deliver triple-digit upside if their key milestones are achieved on time. 
Via InvestorPlace
News headline image
More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics ↗
These companies are innovators, something that can prove highly lucrative. 
Via The Motley Fool
News headline image
CRSP Stock Alert: What to Know as CRISPR Therapeutics Co-Founder Steps Down ↗
With CRISPR Therapeutics announcing the departure of its co-founder, investors are also walking for the exits on CRSP stock. 
Via InvestorPlace
News headline image
2 Brilliant Growth Stocks With Upsides of About 70%, According to Wall Street ↗
Wall Street analysts foresee these pre-commercial-stage drugmakers rocketing higher over the next 12 months. 
Via The Motley Fool
News headline image
With a Prediction for a 70% Gain, Is Wall Street Too Optimistic About This Biotech Stock? ↗
Big news could come in December and in March. 
Via The Motley Fool
News headline image
The 3 Best Biotech Stocks to Buy Now: September 2023 ↗
With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize. 
Via InvestorPlace
News headline image
2 Spectacular Growth Stocks You Can Buy in September With No Hesitation ↗
There's no need for any anxiety with investing in these great stocks. 
Via The Motley Fool
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.